Accelerating Adoption of Hypofractionation in Breast Cancer through Clinical Pathways and Peer Review

March 9, 2023

References to support the NCCN poster presentation

1. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Breast Cancer Version 4.2022. 2022 June 21; National Comprehensive Cancer Network. Available from:

2. Mitin T, Kubicky CD. The Use of Hypofractionated Whole Breast Irradiation in Treatment of Patients With Early-Stage Breast Cancer in the United States. JAMA Oncol. 2015;1(2):245–246.

3. Niska JR, Keole SR, et al. Choosing wisely after publication of level I evidence in breast cancer radiotherapy. Breast Cancer (Dove Med Press). 2018 Feb 9;10:31-37.

4. Bekelman JE, Sylwestrzak G, Barron J, et al. Uptake and Costs of Hypofractionated vs Conventional Whole Breast Irradiation After Breast Conserving Surgery in the United States, 2008–2013. JAMA. 2014;312(23):2542–2550.

5. Jagsi R, Falchook AD, et al. Adoption of Hypofractionated Radiation Therapy for Breast Cancer After Publication of Randomized Trials. International Journal of Radiation Oncology*Biology*Physics, Volume 90, Issue 5, 2014, 1001-1009.

6. Kang MM, Hasan Y, et al. Has Hypofractionated Whole-Breast Radiation Therapy Become the Standard of Care in the United States? An Updated Report from National Cancer Database, Clinical Breast Cancer, Volume 22, Issue 1, 2022, Pages e8-e20,

7. Rodríguez-Lopéz JL, Ling DC, et al. Lag Time Between Evidence and Guidelines: Can Clinical Pathways Bridge the Gap? Journal of Oncology Practice 15, no. 3 (March 01, 2019) e195-e201.

Ganju RG, TenNapel M, et al. Impact of Peer Review on Use of Hypofractionated Regimens for Early-Stage Breast Cancer for Patients at a Tertiary Care Academic Medical Center and Its Community-Based Affiliates. Journal of Oncology Practice 2019 15:2

No Previous Articles

Next Article
Trends Impacting the Future of Cancer Care
Trends Impacting the Future of Cancer Care

Our VP of market strategy shares her insights with Becker's Hospital Review.


First Name
Last Name
Company Name
Thank you!
Error - something went wrong!